2326522-16-9
Chemical Structure
KRAS G12C inhibitor 39
- CAS No.: 2326522-16-9
- Formula:C37H43N9O2
- Molecular Weight:645.80
IUPAC Name: 2-((S)-1-((E)-3-(1-methyl-1H-pyrazol-4-yl)acryloyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile
InChIKey: XLWQRAXKTKNFIV-QFFHNCJUSA-N
SMILES: N#CC[C@@H]1N(C(/C=C/C2=CN(C)N=C2)=O)CCN(C3=C4C(CN(C5=C6C(C)=CC=CC6=CC=C5)CC4)=NC(OC[C@H]7N(C)CCC7)=N3)C1
Biological Activity: KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494)[1].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KRAS G12C inhibitor 39 | KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
